Altimmune (Altimmune) Change In Receivables : $0.79 Mil (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Altimmune Change In Receivables?

Altimmune's change in receivables for the quarter that ended in Mar. 2024 was $2.27 Mil. It means Altimmune's Accounts Receivable declined by $2.27 Mil from Dec. 2023 to Mar. 2024 .

Altimmune's change in receivables for the fiscal year that ended in Dec. 2023 was $-2.31 Mil. It means Altimmune's Accounts Receivable increased by $2.31 Mil from Dec. 2022 to Dec. 2023 .

Altimmune's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.31 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Altimmune's Days Sales Outstanding for the three months ended in Mar. 2024 was 5,602.75.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Altimmune's liquidation value for the three months ended in Mar. 2024 was $166.83 Mil.

Altimmune Change In Receivables Historical Data

The historical data trend for Altimmune's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Change In Receivables Chart

Altimmune Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

2.82

-10.72

6.53

3.30

-2.31

Altimmune Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.83	-0.34	-0.81	-0.32	2.27

Altimmune Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.79 Mil.

Altimmune (NAS:ALT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Altimmune's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.307	/	0.005	*	91
=	5,602.75

2. In Ben Graham's calculation of liquidation value, Altimmune's accounts receivable are only considered to be worth 75% of book value:

Altimmune's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	182.024	-	15.421	+	0.75 * 0.307	+	0.5 * 0
=	166.83

Altimmune Change In Receivables Related Terms

Thank you for viewing the detailed overview of Altimmune's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune (Altimmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ALT1:Mexico 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Executives

David Drutz	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Catherine A. Sohn	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Matthew Scott Harris	officer: Chief Medical Officer	C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt	officer: Chief Business Officer	ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg	director, officer: President and CEO	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill	director	C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts	officer: Chief Scientific Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky	director	60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges	director	19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018